Arvinas develops protein degrader medicines that aim to remove disease-causing proteins to treat cancer and neurological diseases. It last closed at $6.46 on Nov 20, down 4.15% on the day. The next earnings report for ARVN is expected around Tue, Feb 23, 2027. For the quarter ended Sep 2026, ARVN reported EPS of -$0.82 on revenue of $500,000, with revenue down 98.8% from a year ago. Over its last 8 reports the stock moved an average of 8.3% the session after earnings. Over the last 12 months ARVN insiders bought $268K of stock on the open market and sold $1.4M, according to SEC Form 4 filings.
AI Auto Pilots
Is ARVN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ARVN.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on ARVNStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
ARVN · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold
The stock is 9% below its 20 day and 15% below its 50 day average. It is 43% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 37), near oversold. The nearest support is the 52 week low at $6.33, and the nearest resistance the Pivot at $6.58.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 6.2%/day
Key levels
$14.5152 week high+124.6%
$9.23200 day average+42.9%
$8.06100 day average+24.8%
$7.4050 day average+14.6%
$7.0520 day average+9.1%
$6.96Swing high (Nov 11)+7.7%
$6.74Pivot R1+4.3%
$6.58Pivot+1.9%
$6.46Last close
$6.3352 week low−2.0%
$6.33Swing low (Nov 9)−2.0%
$6.29Pivot S1−2.6%
Indicators
RSI (14)
36.66
Weak, oversold below 30
Neutral
MACD
-0.24
Below its signal line
Bearish
Stochastic
19.8
Near the bottom of its range
Oversold
ADX (14)
25.8
Trending down
Williams %R
-90.7
Oversold below −80, overbought above −20
Oversold
CCI (20)
-82.5
Oversold below −100, overbought above 100
Neutral
Rate of change
+0.8%
Change over 10 sessions
Bullish
ATR (14)
$0.40
Typical daily range, 6.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 14.2%/day
Key levels
$14.5152 week high+124.6%
$9.23200 day average+42.9%
$8.06100 day average+24.8%
$7.4050 day average+14.6%
$7.0520 day average+9.1%
$6.96Swing high (Nov 11)+7.7%
$6.74Pivot R1+4.3%
$6.58Pivot+1.9%
$6.46Last close
$6.3352 week low−2.0%
$6.33Swing low (Nov 9)−2.0%
$6.29Pivot S1−2.6%
Indicators
RSI (14)
36.27
Weak, oversold below 30
Neutral
MACD
-0.73
Below its signal line
Bearish
Stochastic
6.4
Near the bottom of its range
Oversold
ADX (14)
21.1
Weak trend
Williams %R
-96.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-138.4
Oversold below −100, overbought above 100
Oversold
Rate of change
−23.6%
Change over 10 sessions
Bearish
ATR (14)
$0.92
Typical daily range, 14.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ARVN
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how ARVN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow ARVN usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for ARVNHow many large options trades hit ARVN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in ARVN in the last 90 days.
From SEC Form 4 filings by ARVN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARVN is in one of them and how their past ARVN trades turned out.
Arvinas is a biotechnology company based in New Haven, Connecticut. It develops medicines that use targeted protein degradation, a method that removes disease-causing proteins from cells by using the body's own protein disposal system. Its drug candidates focus mainly on cancer and neurological diseases such as Parkinson's disease, and several are in clinical trials with patients. The company also works with larger drug makers, including Pfizer and Genentech, on early-stage research.